Epigenetic-based therapies in the preclinical and clinical treatment of Huntington's disease.
The study of epigenetics is providing novel insights about the functional and developmental complexity of the nervous system. In neuropathology, therapies aimed at correcting epigenetic dysregulation have been extensively documented in a large variety of models for neurodegenerative, neurodevelopmental and psychiatric disorders. Taking the treatment of Huntington's disease as a paradigm for the study of these ameliorative strategies, this review updates the main conclusions derived from the use of epigenetic drugs at the preclinical and clinical stages, including actions beyond epigenetics. This article is part of a Directed Issue entitled: Epigenetics dynamics in development and disease.
Instituto de Neurociencias de Alicante (Universidad Miguel Hernández - Consejo Superior de Investigaciones Científicas), Av. Santiago Ramón y Cajal s/n, Sant Joan d'Alacant, 03550 Alicante, Spain. Electronic address: lmv@umh.es.
Luis M
LM
Valor
D000818:Animals; D018943:Anthracyclines / Q000627:therapeutic use*; D002843:Chromatin / Q000737:chemistry / Q000187:drug effects / Q000378:metabolism; D002986:Clinical Trials as Topic; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical; D044127:Epigenesis, Genetic / Q000187:drug effects*; D056572:Histone Deacetylase Inhibitors / Q000627:therapeutic use*; D006657:Histones / Q000378:metabolism; D006801:Humans; D006816:Huntington Disease / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D014158:Transcription, Genetic / Q000187:drug effects
D018943:Anthracyclines; D002843:Chromatin; D056572:Histone Deacetylase Inhibitors; D006657:Histones; D018696:Neuroprotective Agents
Clinical trials; Epigenetics; HDAC inhibitors; Neurodegenerative; Transcription